Sex Hormones in SARS-CoV-2 Susceptibility: Key Players or Confounders?

    December 2022 in “ Nature Reviews Endocrinology ”
    Nicola Lott, Caroline E. Gebhard, Susan Bengs … Cathérine Gebhard
    Studysummary This review discusses the roles of sex hormones in COVID-19 progression and highlights conflicting evidence on their protective effects and the complexity of sex and gender influences on the disease.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on nature.com →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial Cureus · 2021
    2. Immunoreactivity of the SARS-CoV-2 Entry Proteins ACE-2 and TMPRSS-2 in Murine Models of Hormonal Manipulation, Aging, and Cardiac Injury Scientific Reports · 2021
    3. Impact of Androgen Deprivation Therapy on Mortality of Prostate Cancer Patients with COVID-19: A Propensity Score-Based Analysis Infectious Agents and Cancer · 2021
    4. Sex Steroid Hormones Are Associated With Mortality In COVID-19 Patients Medicine · 2021
    5. Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide medRxiv (Cold Spring Harbor Laboratory) · 2021
    6. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial Frontiers in Medicine · 2021
    7. Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial medRxiv (Cold Spring Harbor Laboratory) · 2021
    8. Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial bioRxiv (Cold Spring Harbor Laboratory) · 2021
    9. The Antiandrogen Enzalutamide Downregulates TMPRSS2 and Reduces Cellular Entry of SARS-CoV-2 in Human Lung Cells Nature Communications · 2021
    10. Role of Testosterone in SARS-CoV-2 Infection: A Key Pathogenic Factor and a Biomarker for Severe Pneumonia International Journal of Infectious Diseases · 2021
    11. The Double-Edged Sword of Testosterone’s Role in the COVID-19 Pandemic Frontiers in Endocrinology · 2021
    12. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial Cureus · 2021
    13. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial Cureus · 2021
    14. Testosterone Target Therapy: Focus on Immune Response, Controversies, and Clinical Implications in Patients with COVID-19 Infection Therapeutic Advances in Endocrinology and Metabolism · 2021
    15. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men Cell Stem Cell · 2020
    16. Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign' Journal of The American Academy of Dermatology · 2020
    17. A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity Journal of Cosmetic Dermatology · 2020